Equities research analysts expect Viking Therapeutics Inc (NASDAQ:VKTX) to report earnings of ($0.19) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Viking Therapeutics’ earnings, with estimates ranging from ($0.20) to ($0.19). Viking Therapeutics posted earnings of ($0.18) per share during the same quarter last year, which indicates a negative year over year growth rate of 5.6%. The firm is expected to report its next earnings report on Tuesday, March 20th.
On average, analysts expect that Viking Therapeutics will report full year earnings of ($0.86) per share for the current year, with EPS estimates ranging from ($0.87) to ($0.85). For the next year, analysts expect that the company will post earnings of ($0.68) per share, with EPS estimates ranging from ($0.72) to ($0.60). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Viking Therapeutics.
VKTX has been the subject of several research reports. Roth Capital set a $6.00 target price on Viking Therapeutics and gave the stock a “buy” rating in a report on Wednesday, November 29th. Maxim Group set a $8.00 target price on Viking Therapeutics and gave the stock a “buy” rating in a report on Tuesday, November 28th. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Viking Therapeutics in a report on Friday, November 10th. BidaskClub cut Viking Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 15th. Finally, ValuEngine cut Viking Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $7.00.
Several hedge funds have recently modified their holdings of VKTX. Citadel Advisors LLC purchased a new stake in shares of Viking Therapeutics during the 3rd quarter worth $108,000. Virtu KCG Holdings LLC purchased a new stake in shares of Viking Therapeutics during the 2nd quarter worth $124,000. Creative Planning lifted its stake in shares of Viking Therapeutics by 600.0% during the 4th quarter. Creative Planning now owns 70,000 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 60,000 shares during the last quarter. Cornerstone Capital Inc. purchased a new stake in shares of Viking Therapeutics during the 4th quarter worth $352,000. Finally, Geode Capital Management LLC lifted its stake in shares of Viking Therapeutics by 276.2% during the 4th quarter. Geode Capital Management LLC now owns 117,619 shares of the biotechnology company’s stock worth $477,000 after purchasing an additional 86,355 shares during the last quarter. Institutional investors and hedge funds own 11.72% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Brokerages Anticipate Viking Therapeutics Inc (VKTX) to Announce -$0.19 EPS” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2018/02/20/brokerages-anticipate-viking-therapeutics-inc-vktx-to-announce-0-19-eps.html.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.